Literature DB >> 7990710

Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus.

D Kelley1, M Mokan, T Veneman.   

Abstract

The importance of impaired glucose utilization in the pathogenesis of postprandial hyperglycemia in non-insulin-dependent diabetes mellitus (NIDDM) is controversial. Three methods were used to assess glucose utilization following ingestion of a mixed meal in 18 NIDDM and 12 nondiabetic subjects. Dual glucose isotopes were used to determine first-pass splanchnic glucose uptake, suppression of endogenous glucose production, and systemic glucose utilization. Leg balance was used to evaluate skeletal muscle glucose metabolism, and systemic and limb indirect calorimetry were used to assess glucose and lipid oxidation. NIDDM subjects had marked postprandial hyperglycemia as compared with nondiabetics (15.35 +/- 0.72 v 5.83 +/- 0.28 mmol, P < .001), accompanied by lower postprandial insulin (179 +/- 25 v 253 +/- 46 pmol, P < .01) and elevated plasma free fatty acids ([FFA] 569 +/- 34 v 314 +/- 20 mumol/L, P < .001). Cumulative postprandial glucose appearance was nearly twofold greater in NIDDM (82.2 +/- 4.7 v 48.7 +/- 4.9 g.5h, P < .001) due to increased endogenous glucose production (56.4 +/- 4.8 v 24.5 +/- 1.9 g, P < .001), whereas first-pass splanchnic uptake of ingested glucose was normal in NIDDM. Cumulative postprandial glucose utilization in NIDDM, after correction for urinary glucose, was unchanged from postabsorptive rates, a pattern also found for postprandial glucose oxidation. Cumulative leg glucose uptake was somewhat less in NIDDM subjects (123 +/- 18 v 173 +/- 14 mumol/100 mL leg tissue.5 h, P = .06), whereas lactate and alanine net release across the leg were nevertheless twofold greater in NIDDM (P = .04) and accounted for nearly half of the leg glucose metabolism in NIDDM.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990710     DOI: 10.1016/0026-0495(94)90015-9

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

Review 1.  The role of the liver in type 2 diabetes.

Authors:  Peter Staehr; Ole Hother-Nielsen; Henning Beck-Nielsen
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

Review 2.  Skeletal muscle fat oxidation: timing and flexibility are everything.

Authors:  David E Kelley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

3.  Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.

Authors:  A Basu; A Alzaid; S Dinneen; A Caumo; C Cobelli; R A Rizza
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

4.  Roux-en-Y gastric bypass surgery improves hepatic glucose metabolism and reduces plasma kisspeptin levels in morbidly obese patients with type 2 diabetes.

Authors:  C Robb Flynn; Vance L Albaugh; Robyn A Tamboli; Justin M Gregory; Amma Bosompem; Reem M Sidani; Jason J Winnick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

5.  Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor.

Authors:  Barbara Ukropcova; Michele McNeil; Olga Sereda; Lilian de Jonge; Hui Xie; George A Bray; Steven R Smith
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 6.  Metabolic flexibility and insulin resistance.

Authors:  Jose E Galgani; Cedric Moro; Eric Ravussin
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-02       Impact factor: 4.310

Review 7.  Beta-cell failure in the pathogenesis of type 2 diabetes mellitus.

Authors:  Jeanne H Steppel; Edward S Horton
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

Review 8.  Fat-induced liver insulin resistance.

Authors:  Pankaj Shah; Ananda Basu; Robert Rizza
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

Review 9.  Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.

Authors:  James F McLeod
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism.

Authors:  Ananda Basu; Chiara Dalla Man; Rita Basu; Gianna Toffolo; Claudio Cobelli; Robert A Rizza
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.